What Is Corynebacterium striatum & What Does It Cause?

Corynebacterium striatum is a gram-positive bacterium that lives harmlessly on human skin and mucous membranes in most people but has emerged over the past decade as a serious hospital-acquired pathogen, particularly among patients who are immunocompromised or have chronic lung disease. Once dismissed as a laboratory contaminant whenever it turned up in clinical cultures, C. striatum now causes pneumonia, bloodstream infections, bone infections, heart valve infections, and wound infections that carry mortality rates comparable to those of methicillin-resistant Staphylococcus aureus (MRSA). Its rapid acquisition of resistance to multiple antibiotic classes has made it one of the more worrisome bugs in hospital microbiology labs worldwide.

A Skin Commensal That Crossed a Line

C. striatum belongs to the large genus Corynebacterium, a group of rod-shaped bacteria that are among the most common residents of healthy human skin. It is aerobic and facultatively anaerobic, meaning it can survive with or without oxygen, and it typically coexists peacefully with its human host for an entire lifetime.¹ For decades, microbiologists who found it in wound swabs or blood cultures tended to assume it had simply hitchhiked in from the skin surface during sample collection. A landmark early case series in the 1990s was among the first to argue otherwise, documenting C. striatum as a genuine cause of catheter-site infections, bloodstream infections, and even conjunctivitis.²

What changed the picture was a combination of better identification tools and a growing population of vulnerable hospital patients. Older biochemical test kits frequently misidentified C. striatum as a closely related species. Newer technology, particularly mass-spectrometry-based identification, greatly improved accuracy and revealed that C. striatum was the dominant Corynebacterium species in clinical isolates, accounting for roughly 59% of all Corynebacterium identifications in one hospital survey.³ Once labs could reliably tell C. striatum apart from its relatives, the sheer frequency of its presence in serious infections became hard to ignore.

Who Gets Sick

Most C. striatum infections happen in hospitals, and most patients who develop them share a recognizable profile: weakened immune systems, long hospital stays, invasive medical devices like central venous catheters or endotracheal tubes, and prior courses of broad-spectrum antibiotics. People with chronic structural lung disease, especially chronic obstructive pulmonary disease (COPD), are particularly vulnerable. A well-documented outbreak in a Spanish respiratory unit involved 21 COPD patients over a relatively short period, with 11 isolates appearing within a single month.⁴

A genomics study that tracked multidrug-resistant C. striatum infections across institutions found that all seven flagged cases occurred specifically in immunocompromised patients with underlying respiratory diseases.⁵ That said, it is not exclusively an infection of the severely ill. Cases of community-acquired pneumonia in people with apparently normal immune function have been reported, and there is evidence of person-to-person transmission through healthcare workers’ hands.⁶

The Infections It Causes

C. striatum is not a one-trick pathogen. It has been convincingly linked to infections in many different body sites, and the range has expanded as clinicians have learned to take it seriously rather than dismiss it as a contaminant.

Pneumonia

Severe pneumonia is probably the best-studied manifestation. A six-year observational study in Seoul tracked severe pneumonia cases across a hospital system and found 27 caused by C. striatum. The proportion of severe hospital-acquired pneumonia attributable to C. striatum rose from about 1% in 2014–2015 to over 5% in 2018–2019, while MRSA-caused severe pneumonia fell from 12% to under 3% over the same period. Most C. striatum pneumonia patients had acquired their infection in the hospital, and roughly half were immunocompromised. The 90-day mortality rate was about 59%, statistically indistinguishable from the MRSA group’s 50.5%.⁷ A case report of an HIV-positive man with multiple comorbidities reinforced the severity: after C. striatum was isolated from respiratory samples, his condition worsened rapidly, requiring intubation, and he ultimately died.⁸

Bloodstream Infections and Endocarditis

When C. striatum enters the bloodstream, the consequences are serious. A study of Corynebacterium bloodstream infections in Japan found that about 70% of C. striatum blood cultures represented true bacteremia rather than contamination, a far higher proportion than most other Corynebacterium species, where the true-infection rate was only about 9%. The 90-day mortality for C. striatum bacteremia was 34%.⁹ Bacteremia can progress to infective endocarditis, an infection of the heart valves. Case reports describe both native and prosthetic valve endocarditis caused by C. striatum, with vegetation on the mitral valve confirmed by echocardiography.¹⁰ One particularly instructive case involved a patient who developed native-valve endocarditis from C. striatum after receiving two prolonged courses of daptomycin for MRSA, illustrating how heavy antibiotic use can select for resistant skin flora that then invades.¹¹

Bone and Joint Infections

C. striatum has a particular affinity for orthopedic settings. In a systematic review of 52 cases of Corynebacterium-caused prosthetic joint infections (PJI), C. striatum was the species responsible in about 71% of cases.¹² One institution reported a statistically significant jump in the proportion of PJI cases caused by C. striatum over just 16 months.¹³ In chronic osteomyelitis (deep bone infection), a case series concluded that C. striatum is often a true pathogen, not merely a bystander in a mixed-infection culture, and that targeted antibiotic therapy against it, combined with surgery, is typically needed for cure.¹⁴

Wound Infections

People with chronic wounds on the lower extremities, especially diabetic foot ulcers and venous leg ulcers, are at elevated risk. A prospective study of hard-to-heal peripheral wounds found that C. striatum infection correlated with foot ulcers, venous leg ulcers, impaired blood flow, hospitalization, malignancy, spinal cord injury, and recent antibiotic use.¹⁵ Among patients with diabetic foot osteomyelitis, having received antibiotics for more than 14 days was an independent risk factor for C. striatum being the causative organism, with about a threefold increase in odds.¹⁶

How It Sticks Around

One reason C. striatum is so successful in hospital settings is its ability to form biofilms, the slimy protective communities that bacteria build on surfaces. Research has shown that C. striatum can adhere to both water-attracting and water-repelling surfaces, including the polyurethane used in catheters. The bacterium binds fibrinogen, a blood protein, to its outer surface, which helps cement the biofilm together. Scanning electron microscopy has confirmed mature biofilms on catheter material.¹⁷ Strains isolated from patients on endotracheal tubes showed the strongest adhesion ability, which fits with the clinical picture of ventilator-associated infections.

Surface pili, the tiny hair-like structures that many bacteria use to grab onto cells and surfaces, play a role in this stickiness. Most C. striatum isolates carry genes for a type of pilus called spa-type pili, though curiously, the presence of those genes alone doesn’t perfectly predict how much biofilm a given strain produces.¹⁸ Lab experiments also showed that multidrug-resistant strains could infect and kill the model organism C. elegans (a tiny roundworm used in virulence testing) within five days, and virulence was associated with the pilus gene cluster.¹⁹

Beyond living surfaces, biofilms on steel and other hard hospital surfaces make C. striatum hard to eradicate from the environment. Testing of common hospital disinfectants revealed that the bacteria could survive glutaraldehyde exposure for up to 30 minutes in some strains, and that mature biofilms were substantially harder to kill than free-floating bacteria. The presence of organic matter, such as bodily fluids, reduced the effectiveness of every disinfectant tested. Peracetic acid, sodium hypochlorite, and ethyl alcohol performed better than glutaraldehyde, but hospital staff need to be aware that standard cleaning protocols may not fully eliminate biofilm-protected C. striatum.²⁰

Spreading Through Hospitals

Whole-genome sequencing has confirmed what infection-control teams had feared: C. striatum can spread persistently within a hospital for years. In one detailed genomic investigation, 192 isolates were separated into 79 distinct strain types by pulsed-field gel electrophoresis, but two dominant subtypes were responsible for hospital-wide dissemination. The genome data also showed that these circulating strains progressively picked up resistance genes over time, with nine resistance genes mobilized by eight different genetic cassettes.²¹ In other words, the longer the bug circulates in a hospital, the more resistant it becomes.

A more recent genomic study identified a potentially hypervirulent and multidrug-resistant cluster of C. striatum strains, designated SC3. These strains carried a higher number of virulence genes, including four pilus-related genes that appeared unique to the cluster. Gene analysis suggested enhanced DNA-repair and recombination capabilities, which could help explain how such strains accumulate resistance while maintaining fitness.²² Studies from Brazil have similarly found strong evidence of clonal spread among hospital isolates, though some strains show divergent profiles, suggesting that C. striatum outbreaks can involve both dominant clonal lineages and independent introductions.²³

The Drug-Resistance Problem

Drug resistance is the single biggest reason C. striatum has climbed from nuisance to genuine threat. Most strains circulating in hospitals are now resistant to many of the antibiotics typically used against gram-positive bacteria, including penicillin, ceftriaxone, meropenem, clindamycin, and tetracycline.²⁴ The mechanisms behind this resistance are diverse. Beta-lactamase enzymes break down penicillins and cephalosporins. Point mutations in the gyrase gene confer quinolone resistance. Methylase enzymes encoded by erm(X) genes block macrolide and lincosamide antibiotics from binding to their targets. Efflux pumps actively eject tetracycline from the cell.²⁵

The most alarming resistance story involves daptomycin, a last-resort antibiotic frequently used when other options have failed. C. striatum can develop sky-high resistance to daptomycin extremely rapidly. In one documented case, a patient’s isolate went from fully susceptible to completely resistant (with a more than 2,000-fold increase in the minimum inhibitory concentration) after just two months of daptomycin therapy.²⁶ A multicenter study found that roughly a third of Corynebacterium isolates could develop daptomycin nonsusceptibility in the lab after short exposure, and C. striatum was among the species affected.²⁷ In patients actually treated with daptomycin for C. striatum bacteremia, nonsusceptibility emerged in over a third and clinical failure occurred in close to half.²⁸

Treatment Options

Given the breadth of resistance, treatment choices are limited and must be guided by susceptibility testing of the specific isolate. A systematic review of antibiotic treatment for invasive C. striatum infections found that vancomycin, linezolid, and teicoplanin retained near-universal activity across tested strains. Vancomycin, either alone or combined with piperacillin-tazobactam, is generally recommended as the first-line choice for serious infections. Linezolid, teicoplanin, or daptomycin can serve as alternatives in severe cases, though the daptomycin resistance issue described above makes it a risky bet for prolonged use. For milder infections, amoxicillin-clavulanate may work if the isolate tests susceptible. Despite appropriate antibiotic therapy, fatal outcomes were reported in close to 20% of patients in the systematic review.²⁹

For bone and joint infections, antibiotics alone are rarely enough. Surgical debridement or prosthesis revision is typically part of the treatment plan. One case of prosthetic joint infection was successfully managed with long-term dalbavancin, a newer long-acting lipoglycopeptide antibiotic that allows once-weekly dosing, though experience with this approach is still limited to individual case reports.³⁰

How C. striatum Compares to Other Corynebacteria

The genus Corynebacterium contains many species, and most are harmless commensals. C. striatum stands out for its frequency, virulence, and resistance profile. A broad review of Corynebacterium species in clinical infections noted that C. striatum and C. jeikeium are responsible for the largest share of bloodstream and orthopedic infections among coryneform gram-positive rods. Other species occupy narrower niches: C. macginleyi for eye infections, C. otitidis for ear infections, C. urealyticum for a distinctive bladder condition called encrusted cystitis, and C. kroppenstedtii for breast abscesses.³¹

An important historical note: in early reports from the 1990s, C. striatum isolates were still broadly susceptible to penicillin, aminoglycosides, and ciprofloxacin, a stark contrast to the multidrug-resistant strains now dominating hospitals.² The speed of this transformation from generally susceptible to broadly resistant over roughly 25 years mirrors patterns seen in other hospital pathogens, though the ability to accumulate resistance genes while maintaining virulence appears especially pronounced in C. striatum.

Why Labs Still Struggle with It

One of the practical frustrations with C. striatum is that many microbiology labs, especially in resource-limited settings, still lack the technology for confident identification. Older phenotypic identification kits can confuse C. striatum with C. amycolatum, a closely related species with a different resistance profile, requiring extra biochemical tests to tell them apart.³² Mass spectrometry identification is fast and accurate but requires expensive equipment. The result is that C. striatum infections are probably undercounted in many parts of the world, and some infections attributed to “Corynebacterium species” or simply “diphtheroid contaminant” are likely C. striatum that no one identified correctly.

The clinical implication is straightforward: when a Corynebacterium isolate appears in a good-quality clinical specimen from a sick patient, dismissing it as skin contamination can be a dangerous mistake. This is especially true when the same organism grows from repeated cultures, when the patient is immunocompromised or has an indwelling device, and when no other pathogen is identified. Getting the specimen to a lab capable of species-level identification and susceptibility testing can make the difference between targeted therapy and a fatal oversight.

Biofilm-Busting Research

Because biofilms are central to the organism’s persistence on devices and hospital surfaces, researchers have been exploring ways to disrupt them. Lab experiments with enzymes that degrade the structural components of biofilms showed promising results. Proteinase K, which chews up proteins in the biofilm matrix, eliminated biofilms in all tested C. striatum strains with moderate to strong biofilm production. DNase I, which breaks down extracellular DNA, worked in 90% of such strains, and dispersin B, which targets a polysaccharide component, was effective in 80%.¹⁸ These are still laboratory findings, not clinical treatments, but they point toward future strategies that might be combined with antibiotics to tackle device-associated infections. For now, prevention through rigorous hand hygiene, environmental cleaning with effective agents, and prudent antibiotic stewardship remains the most practical defense against this once-overlooked organism.